Nichole Carlson
Concepts (546)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sarcoidosis, Pulmonary | 4 | 2026 | 86 | 2.350 |
Why?
| | Sarcoidosis | 3 | 2026 | 163 | 1.750 |
Why?
| | Tomography, X-Ray Computed | 6 | 2026 | 2765 | 1.420 |
Why?
| | Bayes Theorem | 6 | 2020 | 418 | 1.200 |
Why?
| | Luteinizing Hormone | 11 | 2020 | 183 | 1.040 |
Why?
| | Outpatients | 8 | 2025 | 421 | 1.000 |
Why?
| | Models, Statistical | 6 | 2020 | 671 | 0.950 |
Why?
| | Hydrocortisone | 6 | 2015 | 318 | 0.860 |
Why?
| | Radiography, Thoracic | 3 | 2026 | 179 | 0.840 |
Why?
| | Hormones | 3 | 2017 | 140 | 0.800 |
Why?
| | Emphysema | 1 | 2023 | 116 | 0.750 |
Why?
| | Hypothalamo-Hypophyseal System | 7 | 2017 | 207 | 0.700 |
Why?
| | Lung | 6 | 2026 | 4136 | 0.700 |
Why?
| | Pulmonary Emphysema | 1 | 2023 | 312 | 0.650 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2025 | 774 | 0.650 |
Why?
| | Diabetes Complications | 1 | 2022 | 224 | 0.640 |
Why?
| | Data Interpretation, Statistical | 3 | 2017 | 377 | 0.640 |
Why?
| | Disease Susceptibility | 1 | 2021 | 353 | 0.590 |
Why?
| | Metadata | 1 | 2018 | 16 | 0.580 |
Why?
| | State Health Plans | 2 | 2008 | 34 | 0.550 |
Why?
| | Computer Simulation | 4 | 2017 | 1015 | 0.550 |
Why?
| | Follicle Stimulating Hormone | 9 | 2023 | 243 | 0.520 |
Why?
| | Models, Biological | 3 | 2017 | 1828 | 0.520 |
Why?
| | Ovary | 3 | 2017 | 225 | 0.520 |
Why?
| | Adrenocorticotropic Hormone | 2 | 2015 | 148 | 0.500 |
Why?
| | Genome | 1 | 2018 | 303 | 0.490 |
Why?
| | Reproduction | 1 | 2017 | 206 | 0.490 |
Why?
| | Humans | 98 | 2026 | 141749 | 0.480 |
Why?
| | Alzheimer Disease | 5 | 2025 | 595 | 0.470 |
Why?
| | Child Health Services | 2 | 2008 | 196 | 0.470 |
Why?
| | Residence Characteristics | 6 | 2010 | 368 | 0.460 |
Why?
| | Female | 75 | 2026 | 75943 | 0.450 |
Why?
| | Contraceptives, Oral, Combined | 7 | 2011 | 18 | 0.450 |
Why?
| | Adult | 54 | 2026 | 39391 | 0.440 |
Why?
| | Health Services for the Aged | 2 | 2019 | 73 | 0.430 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2021 | 623 | 0.430 |
Why?
| | Biometry | 2 | 2017 | 70 | 0.430 |
Why?
| | Software | 2 | 2019 | 678 | 0.430 |
Why?
| | Brain Injuries | 5 | 2010 | 502 | 0.420 |
Why?
| | Obesity | 12 | 2023 | 3008 | 0.420 |
Why?
| | Middle Aged | 40 | 2026 | 34647 | 0.420 |
Why?
| | Computational Biology | 1 | 2018 | 664 | 0.410 |
Why?
| | Pulsatile Flow | 1 | 2013 | 55 | 0.400 |
Why?
| | Antiparkinson Agents | 3 | 2009 | 40 | 0.400 |
Why?
| | Environment Design | 3 | 2010 | 26 | 0.400 |
Why?
| | Antibodies, Viral | 5 | 2024 | 656 | 0.390 |
Why?
| | Dehydroepiandrosterone | 1 | 2013 | 51 | 0.390 |
Why?
| | Respiratory Function Tests | 3 | 2026 | 560 | 0.390 |
Why?
| | Antibodies, Monoclonal | 6 | 2025 | 1474 | 0.390 |
Why?
| | Circadian Rhythm | 4 | 2013 | 515 | 0.380 |
Why?
| | Aged | 29 | 2025 | 24746 | 0.380 |
Why?
| | Health Services Accessibility | 4 | 2010 | 1027 | 0.370 |
Why?
| | Male | 47 | 2026 | 70179 | 0.360 |
Why?
| | Specimen Handling | 1 | 2013 | 182 | 0.350 |
Why?
| | Antibodies, Neutralizing | 5 | 2025 | 323 | 0.350 |
Why?
| | Gonadotropins | 3 | 2023 | 40 | 0.350 |
Why?
| | Saliva | 1 | 2013 | 251 | 0.350 |
Why?
| | Walking | 4 | 2010 | 548 | 0.330 |
Why?
| | White Matter | 2 | 2023 | 148 | 0.320 |
Why?
| | Levodopa | 2 | 2007 | 39 | 0.320 |
Why?
| | Oregon | 8 | 2011 | 79 | 0.320 |
Why?
| | Hypogonadism | 2 | 2015 | 92 | 0.310 |
Why?
| | Endocrine System | 1 | 2009 | 21 | 0.310 |
Why?
| | Hospitalization | 8 | 2024 | 2264 | 0.300 |
Why?
| | Activities of Daily Living | 3 | 2010 | 427 | 0.300 |
Why?
| | Statistics as Topic | 3 | 2025 | 302 | 0.300 |
Why?
| | Testosterone | 2 | 2010 | 405 | 0.290 |
Why?
| | Parkinson Disease | 4 | 2009 | 571 | 0.290 |
Why?
| | Cohort Studies | 8 | 2026 | 5815 | 0.290 |
Why?
| | Technology | 1 | 2009 | 94 | 0.280 |
Why?
| | Prenatal Care | 1 | 2010 | 303 | 0.280 |
Why?
| | Estradiol | 6 | 2023 | 528 | 0.280 |
Why?
| | Cerebral Ventricles | 1 | 2007 | 55 | 0.270 |
Why?
| | Levonorgestrel | 4 | 2011 | 36 | 0.270 |
Why?
| | Cognition Disorders | 3 | 2008 | 518 | 0.270 |
Why?
| | Metrorrhagia | 3 | 2011 | 4 | 0.270 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2022 | 2537 | 0.270 |
Why?
| | Health Behavior | 3 | 2010 | 792 | 0.260 |
Why?
| | Methylphenidate | 1 | 2007 | 43 | 0.260 |
Why?
| | Perception | 2 | 2007 | 378 | 0.260 |
Why?
| | Dopamine Uptake Inhibitors | 1 | 2007 | 60 | 0.250 |
Why?
| | Aged, 80 and over | 12 | 2025 | 7923 | 0.250 |
Why?
| | Young Adult | 15 | 2024 | 13749 | 0.250 |
Why?
| | Smoking Cessation | 1 | 2010 | 440 | 0.250 |
Why?
| | Time Factors | 13 | 2017 | 6966 | 0.230 |
Why?
| | Longitudinal Studies | 10 | 2020 | 2938 | 0.220 |
Why?
| | Poverty | 2 | 2010 | 530 | 0.220 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2022 | 3789 | 0.220 |
Why?
| | Cluster Analysis | 2 | 2023 | 521 | 0.220 |
Why?
| | Gliosis | 2 | 2023 | 28 | 0.220 |
Why?
| | Health Care Rationing | 1 | 2024 | 60 | 0.210 |
Why?
| | Adenosine Monophosphate | 1 | 2024 | 73 | 0.210 |
Why?
| | Brain Ischemia | 2 | 2017 | 350 | 0.210 |
Why?
| | Healthcare Disparities | 1 | 2010 | 673 | 0.210 |
Why?
| | Denmark | 2 | 2021 | 47 | 0.210 |
Why?
| | Alanine | 1 | 2024 | 158 | 0.210 |
Why?
| | Medicaid | 1 | 2008 | 451 | 0.200 |
Why?
| | Neurology | 1 | 2025 | 112 | 0.200 |
Why?
| | Spirometry | 2 | 2024 | 260 | 0.200 |
Why?
| | Risk Factors | 10 | 2022 | 10482 | 0.190 |
Why?
| | Oocytes | 2 | 2020 | 179 | 0.190 |
Why?
| | Retrospective Studies | 13 | 2024 | 16374 | 0.190 |
Why?
| | Body Mass Index | 6 | 2019 | 2385 | 0.190 |
Why?
| | Neuropsychological Tests | 3 | 2025 | 1093 | 0.190 |
Why?
| | Socioeconomic Factors | 5 | 2010 | 1317 | 0.190 |
Why?
| | Benchmarking | 1 | 2023 | 180 | 0.180 |
Why?
| | Markov Chains | 3 | 2017 | 126 | 0.180 |
Why?
| | Monte Carlo Method | 3 | 2017 | 150 | 0.180 |
Why?
| | Aging | 4 | 2008 | 1924 | 0.180 |
Why?
| | Prospective Studies | 9 | 2023 | 7777 | 0.180 |
Why?
| | Antiviral Agents | 2 | 2024 | 747 | 0.170 |
Why?
| | Cross-Sectional Studies | 12 | 2018 | 5697 | 0.170 |
Why?
| | Disability Evaluation | 4 | 2018 | 304 | 0.170 |
Why?
| | Doxycycline | 2 | 2011 | 61 | 0.170 |
Why?
| | Ethinyl Estradiol | 2 | 2011 | 15 | 0.170 |
Why?
| | Oocyte Donation | 1 | 2020 | 4 | 0.170 |
Why?
| | Preimplantation Diagnosis | 1 | 2020 | 5 | 0.170 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2022 | 98 | 0.170 |
Why?
| | Healthy Aging | 1 | 2021 | 37 | 0.170 |
Why?
| | Weight Gain | 2 | 2022 | 539 | 0.170 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 2021 | 112 | 0.170 |
Why?
| | Memory, Episodic | 1 | 2021 | 53 | 0.160 |
Why?
| | Prescription Drugs | 1 | 2022 | 116 | 0.160 |
Why?
| | Myocardial Infarction | 2 | 2017 | 1069 | 0.160 |
Why?
| | Reproductive Techniques, Assisted | 1 | 2020 | 40 | 0.160 |
Why?
| | Cytomegalovirus Infections | 1 | 2022 | 197 | 0.160 |
Why?
| | Cross-Over Studies | 6 | 2025 | 582 | 0.160 |
Why?
| | Apomorphine | 3 | 2009 | 7 | 0.160 |
Why?
| | Proton Pump Inhibitors | 2 | 2017 | 109 | 0.160 |
Why?
| | Menstruation | 2 | 1991 | 42 | 0.160 |
Why?
| | Fractals | 1 | 2019 | 8 | 0.160 |
Why?
| | Aromatase Inhibitors | 1 | 2020 | 58 | 0.160 |
Why?
| | Comprehensive Health Care | 1 | 2019 | 23 | 0.160 |
Why?
| | Nerve Compression Syndromes | 1 | 1999 | 22 | 0.150 |
Why?
| | Radial Nerve | 1 | 1999 | 10 | 0.150 |
Why?
| | Reproducibility of Results | 3 | 2025 | 3356 | 0.150 |
Why?
| | Severity of Illness Index | 7 | 2024 | 2903 | 0.150 |
Why?
| | Internet | 2 | 2018 | 690 | 0.150 |
Why?
| | Human Growth Hormone | 2 | 2014 | 48 | 0.150 |
Why?
| | Astrocytes | 1 | 2021 | 217 | 0.150 |
Why?
| | Health Status | 3 | 2010 | 824 | 0.150 |
Why?
| | Machine Learning | 1 | 2024 | 556 | 0.150 |
Why?
| | Hip Fractures | 1 | 2019 | 86 | 0.140 |
Why?
| | Proportional Hazards Models | 3 | 2017 | 1268 | 0.140 |
Why?
| | Vital Capacity | 1 | 2019 | 306 | 0.140 |
Why?
| | Quality of Life | 5 | 2018 | 3014 | 0.140 |
Why?
| | Biomedical Research | 1 | 2025 | 708 | 0.140 |
Why?
| | Datasets as Topic | 1 | 2018 | 125 | 0.140 |
Why?
| | Bibliometrics | 1 | 2018 | 65 | 0.140 |
Why?
| | Sheep, Domestic | 1 | 2017 | 34 | 0.140 |
Why?
| | Regression Analysis | 2 | 2019 | 1023 | 0.140 |
Why?
| | Case-Control Studies | 5 | 2021 | 3597 | 0.140 |
Why?
| | Contraception | 2 | 1991 | 166 | 0.140 |
Why?
| | Anxiety | 1 | 2025 | 1090 | 0.140 |
Why?
| | Eligibility Determination | 2 | 2008 | 68 | 0.130 |
Why?
| | Reproductive Physiological Phenomena | 1 | 2017 | 1 | 0.130 |
Why?
| | Algorithms | 3 | 2017 | 1768 | 0.130 |
Why?
| | Adolescent | 14 | 2024 | 22130 | 0.130 |
Why?
| | Rhinitis | 2 | 2010 | 173 | 0.130 |
Why?
| | Medically Uninsured | 2 | 2008 | 136 | 0.130 |
Why?
| | Glomerular Filtration Rate | 1 | 2021 | 752 | 0.130 |
Why?
| | Metabolic Diseases | 1 | 2018 | 114 | 0.130 |
Why?
| | Family Planning Services | 2 | 2008 | 91 | 0.130 |
Why?
| | Psychomotor Performance | 3 | 2009 | 329 | 0.130 |
Why?
| | Lactation | 1 | 2018 | 192 | 0.130 |
Why?
| | Premature Birth | 1 | 2020 | 368 | 0.130 |
Why?
| | Hypothyroidism | 2 | 2007 | 73 | 0.130 |
Why?
| | Affect | 3 | 2008 | 316 | 0.130 |
Why?
| | Double-Blind Method | 7 | 2011 | 1989 | 0.120 |
Why?
| | Low Back Pain | 1 | 2018 | 108 | 0.120 |
Why?
| | Endoscopy | 2 | 2010 | 324 | 0.120 |
Why?
| | Antibodies | 1 | 2018 | 411 | 0.120 |
Why?
| | Dietary Fats | 1 | 2018 | 300 | 0.120 |
Why?
| | Maternal Nutritional Physiological Phenomena | 1 | 2018 | 180 | 0.120 |
Why?
| | Sinusitis | 2 | 2010 | 239 | 0.120 |
Why?
| | Pregnancy | 8 | 2023 | 7092 | 0.120 |
Why?
| | Immunologic Memory | 1 | 2018 | 360 | 0.120 |
Why?
| | Models, Animal | 1 | 2017 | 396 | 0.120 |
Why?
| | Pneumonia, Viral | 1 | 2021 | 374 | 0.120 |
Why?
| | Brain | 6 | 2023 | 2868 | 0.120 |
Why?
| | Personnel Selection | 1 | 2016 | 87 | 0.120 |
Why?
| | Recovery of Function | 2 | 2010 | 684 | 0.110 |
Why?
| | Otolaryngology | 1 | 2016 | 106 | 0.110 |
Why?
| | Patient Dropouts | 1 | 2015 | 65 | 0.110 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2015 | 119 | 0.110 |
Why?
| | Growth Hormone-Secreting Pituitary Adenoma | 1 | 2014 | 12 | 0.110 |
Why?
| | Acromegaly | 1 | 2014 | 16 | 0.110 |
Why?
| | Pulmonary Embolism | 1 | 2017 | 239 | 0.110 |
Why?
| | Pituitary-Adrenal System | 3 | 2013 | 172 | 0.110 |
Why?
| | Menstrual Cycle | 3 | 2011 | 134 | 0.110 |
Why?
| | Fatty Acids, Omega-3 | 1 | 2015 | 142 | 0.110 |
Why?
| | Analysis of Variance | 5 | 2009 | 1321 | 0.110 |
Why?
| | Gonadotropin-Releasing Hormone | 4 | 2020 | 213 | 0.110 |
Why?
| | Breast Feeding | 1 | 2018 | 444 | 0.110 |
Why?
| | Drug Administration Schedule | 4 | 2010 | 771 | 0.100 |
Why?
| | Dementia | 2 | 2008 | 263 | 0.100 |
Why?
| | Antibody Formation | 2 | 2022 | 298 | 0.100 |
Why?
| | Biomarkers | 4 | 2021 | 4190 | 0.100 |
Why?
| | Health Care Costs | 1 | 2017 | 427 | 0.100 |
Why?
| | Secretory Rate | 1 | 2013 | 16 | 0.100 |
Why?
| | Decision Support Systems, Clinical | 1 | 2017 | 263 | 0.100 |
Why?
| | Arthritis, Rheumatoid | 1 | 2022 | 1178 | 0.100 |
Why?
| | Immunoenzyme Techniques | 1 | 2013 | 209 | 0.100 |
Why?
| | Electronics | 1 | 2013 | 72 | 0.100 |
Why?
| | Health Policy | 2 | 2024 | 405 | 0.100 |
Why?
| | Arrhythmias, Cardiac | 1 | 2015 | 337 | 0.100 |
Why?
| | Neurosurgical Procedures | 1 | 2014 | 210 | 0.090 |
Why?
| | Interviews as Topic | 3 | 2010 | 854 | 0.090 |
Why?
| | Medical Records | 1 | 2013 | 182 | 0.090 |
Why?
| | Pandemics | 1 | 2021 | 1656 | 0.090 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2015 | 375 | 0.090 |
Why?
| | Age Factors | 8 | 2018 | 3294 | 0.090 |
Why?
| | Adenoma | 1 | 2014 | 221 | 0.090 |
Why?
| | Ventricular Function, Left | 1 | 2015 | 516 | 0.090 |
Why?
| | Urban Health | 2 | 2009 | 95 | 0.090 |
Why?
| | Treatment Outcome | 8 | 2024 | 11181 | 0.090 |
Why?
| | Memory | 3 | 2008 | 263 | 0.090 |
Why?
| | Education, Medical, Graduate | 1 | 2016 | 526 | 0.090 |
Why?
| | Wakefulness | 1 | 2013 | 172 | 0.090 |
Why?
| | Follow-Up Studies | 5 | 2017 | 5212 | 0.090 |
Why?
| | Progestins | 1 | 2011 | 81 | 0.090 |
Why?
| | Dietary Supplements | 1 | 2015 | 570 | 0.090 |
Why?
| | Equipment Design | 1 | 2013 | 525 | 0.090 |
Why?
| | Amenorrhea | 1 | 2011 | 31 | 0.090 |
Why?
| | Dopamine Agonists | 2 | 2008 | 43 | 0.090 |
Why?
| | Contraceptives, Oral, Hormonal | 2 | 2007 | 29 | 0.080 |
Why?
| | Risk Assessment | 2 | 2017 | 3508 | 0.080 |
Why?
| | Cognition | 3 | 2008 | 1228 | 0.080 |
Why?
| | Estrone | 1 | 2010 | 36 | 0.080 |
Why?
| | Birth Certificates | 1 | 2010 | 12 | 0.080 |
Why?
| | Insulin | 1 | 2022 | 2491 | 0.080 |
Why?
| | Birth Rate | 2 | 2020 | 29 | 0.080 |
Why?
| | Dihydrotestosterone | 1 | 2010 | 44 | 0.080 |
Why?
| | Cytokines | 2 | 2015 | 2099 | 0.080 |
Why?
| | Matrix Metalloproteinase Inhibitors | 1 | 2010 | 14 | 0.080 |
Why?
| | Automobile Driving | 2 | 2010 | 152 | 0.080 |
Why?
| | Live Birth | 2 | 2020 | 68 | 0.080 |
Why?
| | Pregnancy Rate | 2 | 2020 | 67 | 0.080 |
Why?
| | Geographic Information Systems | 2 | 2010 | 46 | 0.080 |
Why?
| | Diet | 1 | 2018 | 1282 | 0.080 |
Why?
| | Fertilization in Vitro | 2 | 2020 | 85 | 0.080 |
Why?
| | Thyroxine | 2 | 2007 | 64 | 0.080 |
Why?
| | Cities | 1 | 2010 | 134 | 0.080 |
Why?
| | Sex Factors | 5 | 2018 | 2063 | 0.080 |
Why?
| | Abortion, Induced | 2 | 2008 | 107 | 0.080 |
Why?
| | Personality | 1 | 2011 | 139 | 0.080 |
Why?
| | United States | 6 | 2020 | 15310 | 0.080 |
Why?
| | Electrical Equipment and Supplies | 1 | 2009 | 9 | 0.070 |
Why?
| | Registries | 1 | 2017 | 2144 | 0.070 |
Why?
| | Rehabilitation Centers | 1 | 2009 | 38 | 0.070 |
Why?
| | Pattern Recognition, Automated | 1 | 2009 | 74 | 0.070 |
Why?
| | Stroke | 1 | 2017 | 1158 | 0.070 |
Why?
| | Telecommunications | 1 | 2009 | 21 | 0.070 |
Why?
| | Postmenopause | 1 | 2010 | 371 | 0.070 |
Why?
| | Independent Living | 1 | 2010 | 112 | 0.070 |
Why?
| | Rural Health | 1 | 2009 | 83 | 0.070 |
Why?
| | Progesterone | 3 | 2015 | 263 | 0.070 |
Why?
| | Drug Interactions | 2 | 2007 | 406 | 0.070 |
Why?
| | Mortality | 1 | 2011 | 359 | 0.070 |
Why?
| | Thyrotoxicosis | 1 | 2008 | 8 | 0.070 |
Why?
| | Monitoring, Ambulatory | 1 | 2009 | 90 | 0.070 |
Why?
| | Logistic Models | 2 | 2010 | 2092 | 0.070 |
Why?
| | Ointments | 1 | 2007 | 24 | 0.070 |
Why?
| | Povidone-Iodine | 1 | 2007 | 11 | 0.070 |
Why?
| | Vaccinia | 1 | 2007 | 20 | 0.070 |
Why?
| | Foot | 1 | 2009 | 100 | 0.070 |
Why?
| | Life Change Events | 1 | 2009 | 153 | 0.070 |
Why?
| | Smallpox Vaccine | 1 | 2007 | 24 | 0.070 |
Why?
| | Exercise | 3 | 2010 | 2112 | 0.070 |
Why?
| | Vaccinia virus | 1 | 2007 | 43 | 0.070 |
Why?
| | Pregnancy, Unplanned | 1 | 2008 | 46 | 0.070 |
Why?
| | CD4 Lymphocyte Count | 2 | 2020 | 284 | 0.070 |
Why?
| | Child, Preschool | 4 | 2018 | 11512 | 0.070 |
Why?
| | Parkinsonian Disorders | 1 | 2007 | 43 | 0.070 |
Why?
| | Counseling | 1 | 2010 | 398 | 0.070 |
Why?
| | Disease Progression | 3 | 2015 | 2800 | 0.070 |
Why?
| | Dyskinesia, Drug-Induced | 1 | 2007 | 14 | 0.070 |
Why?
| | Atrophy | 1 | 2007 | 197 | 0.070 |
Why?
| | Population Surveillance | 1 | 2010 | 482 | 0.070 |
Why?
| | Antigens, Bacterial | 1 | 2007 | 125 | 0.060 |
Why?
| | Antibodies, Bacterial | 1 | 2007 | 146 | 0.060 |
Why?
| | Antigens, Viral | 1 | 2007 | 179 | 0.060 |
Why?
| | Awareness | 1 | 2007 | 103 | 0.060 |
Why?
| | Movement | 1 | 2009 | 290 | 0.060 |
Why?
| | Albumins | 1 | 2007 | 116 | 0.060 |
Why?
| | Time Perception | 1 | 2007 | 34 | 0.060 |
Why?
| | Tremor | 1 | 2007 | 97 | 0.060 |
Why?
| | Wounds, Gunshot | 1 | 2009 | 248 | 0.060 |
Why?
| | Blood-Brain Barrier | 1 | 2007 | 145 | 0.060 |
Why?
| | Suicide, Attempted | 1 | 2009 | 394 | 0.060 |
Why?
| | Internship and Residency | 1 | 2016 | 1240 | 0.060 |
Why?
| | Cost-Benefit Analysis | 1 | 2009 | 619 | 0.060 |
Why?
| | Paroxetine | 1 | 2005 | 12 | 0.060 |
Why?
| | Infant | 3 | 2010 | 9843 | 0.060 |
Why?
| | Treatment Failure | 2 | 2022 | 354 | 0.060 |
Why?
| | Emergency Service, Hospital | 1 | 2017 | 2193 | 0.060 |
Why?
| | Animals | 7 | 2023 | 37748 | 0.060 |
Why?
| | Attitude to Health | 1 | 2008 | 458 | 0.050 |
Why?
| | Neurologic Examination | 2 | 2008 | 128 | 0.050 |
Why?
| | Administration, Oral | 1 | 2007 | 803 | 0.050 |
Why?
| | Pulmonary Diffusing Capacity | 1 | 2024 | 76 | 0.050 |
Why?
| | Sensitivity and Specificity | 1 | 2009 | 1977 | 0.050 |
Why?
| | Sexual Behavior | 1 | 2008 | 498 | 0.050 |
Why?
| | Health Promotion | 1 | 2010 | 759 | 0.050 |
Why?
| | Video Recording | 1 | 2025 | 198 | 0.050 |
Why?
| | Likelihood Functions | 2 | 2017 | 147 | 0.050 |
Why?
| | Patient Compliance | 1 | 2008 | 611 | 0.050 |
Why?
| | Follicle Stimulating Hormone, Human | 1 | 2023 | 12 | 0.050 |
Why?
| | United States Food and Drug Administration | 1 | 2024 | 212 | 0.050 |
Why?
| | Child | 5 | 2018 | 22414 | 0.050 |
Why?
| | Colorado | 2 | 2024 | 4629 | 0.050 |
Why?
| | Linear Models | 2 | 2020 | 858 | 0.050 |
Why?
| | Family | 1 | 2008 | 680 | 0.050 |
Why?
| | Neurites | 1 | 2023 | 51 | 0.050 |
Why?
| | Electronic Health Records | 2 | 2024 | 1132 | 0.050 |
Why?
| | Diffusion Tensor Imaging | 1 | 2023 | 78 | 0.050 |
Why?
| | Motor Activity | 1 | 2007 | 720 | 0.050 |
Why?
| | Physical Fitness | 1 | 2004 | 206 | 0.050 |
Why?
| | Ritonavir | 1 | 2023 | 75 | 0.050 |
Why?
| | Temporomandibular Joint Dysfunction Syndrome | 1 | 2002 | 3 | 0.050 |
Why?
| | Facial Pain | 1 | 2002 | 13 | 0.050 |
Why?
| | Vaccines | 1 | 2007 | 406 | 0.050 |
Why?
| | Emotions | 1 | 2007 | 579 | 0.050 |
Why?
| | Urban Population | 1 | 2025 | 485 | 0.050 |
Why?
| | B-Lymphocytes | 1 | 2007 | 859 | 0.050 |
Why?
| | Physical Examination | 2 | 2018 | 242 | 0.050 |
Why?
| | Sex Characteristics | 1 | 2007 | 792 | 0.050 |
Why?
| | Acids | 1 | 2002 | 19 | 0.050 |
Why?
| | Administration, Cutaneous | 2 | 2015 | 129 | 0.050 |
Why?
| | Diffusion Magnetic Resonance Imaging | 1 | 2023 | 156 | 0.050 |
Why?
| | Faculty, Medical | 1 | 2025 | 296 | 0.050 |
Why?
| | Odds Ratio | 3 | 2010 | 1057 | 0.050 |
Why?
| | Practice Patterns, Physicians' | 1 | 2011 | 1344 | 0.050 |
Why?
| | Ovarian Follicle | 1 | 2002 | 72 | 0.040 |
Why?
| | Magnetic Resonance Imaging | 3 | 2008 | 3737 | 0.040 |
Why?
| | Herpesvirus 4, Human | 1 | 2022 | 165 | 0.040 |
Why?
| | Anti-Bacterial Agents | 1 | 2011 | 1866 | 0.040 |
Why?
| | Rheumatoid Factor | 1 | 2022 | 177 | 0.040 |
Why?
| | Neuroimaging | 1 | 2023 | 281 | 0.040 |
Why?
| | Puberty | 1 | 2002 | 152 | 0.040 |
Why?
| | Anti-Citrullinated Protein Antibodies | 1 | 2022 | 118 | 0.040 |
Why?
| | Leadership | 1 | 2025 | 399 | 0.040 |
Why?
| | Oocyte Retrieval | 1 | 2020 | 12 | 0.040 |
Why?
| | Pregnancy, Multiple | 1 | 2020 | 18 | 0.040 |
Why?
| | Immunoglobulin M | 1 | 2022 | 287 | 0.040 |
Why?
| | Immunoglobulin A | 1 | 2022 | 214 | 0.040 |
Why?
| | Patient Acceptance of Health Care | 1 | 2007 | 881 | 0.040 |
Why?
| | Blastocyst | 1 | 2020 | 47 | 0.040 |
Why?
| | Leptin | 1 | 2002 | 242 | 0.040 |
Why?
| | Embryo Transfer | 1 | 2020 | 35 | 0.040 |
Why?
| | Fasting | 1 | 2002 | 284 | 0.040 |
Why?
| | Breast Neoplasms | 2 | 2011 | 2257 | 0.040 |
Why?
| | Prostaglandins | 1 | 2000 | 101 | 0.040 |
Why?
| | Radionuclide Imaging | 1 | 2019 | 120 | 0.040 |
Why?
| | Surveys and Questionnaires | 3 | 2025 | 5974 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2009 | 2064 | 0.040 |
Why?
| | Endotoxins | 1 | 2000 | 220 | 0.040 |
Why?
| | Oligodendroglia | 1 | 2001 | 179 | 0.040 |
Why?
| | Vaccination | 2 | 2024 | 1472 | 0.040 |
Why?
| | Decompression, Surgical | 1 | 1999 | 115 | 0.040 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2007 | 1406 | 0.040 |
Why?
| | Receptors, Nicotinic | 1 | 2001 | 344 | 0.040 |
Why?
| | Immunization, Secondary | 1 | 2018 | 92 | 0.040 |
Why?
| | Depression | 1 | 2008 | 1508 | 0.040 |
Why?
| | Predictive Value of Tests | 2 | 2018 | 2075 | 0.030 |
Why?
| | Immunoglobulin G | 1 | 2022 | 900 | 0.030 |
Why?
| | Controlled Before-After Studies | 1 | 2017 | 14 | 0.030 |
Why?
| | Milk | 1 | 2018 | 123 | 0.030 |
Why?
| | Confidence Intervals | 2 | 2008 | 329 | 0.030 |
Why?
| | Depressive Disorder | 1 | 2000 | 395 | 0.030 |
Why?
| | Protons | 1 | 2017 | 94 | 0.030 |
Why?
| | Genetic Testing | 1 | 2020 | 463 | 0.030 |
Why?
| | Biostatistics | 1 | 2017 | 18 | 0.030 |
Why?
| | Psychological Tests | 1 | 2018 | 136 | 0.030 |
Why?
| | Signal-To-Noise Ratio | 1 | 2017 | 67 | 0.030 |
Why?
| | Incidence | 2 | 2017 | 2806 | 0.030 |
Why?
| | Electromyography | 1 | 1999 | 411 | 0.030 |
Why?
| | Thyrotropin | 2 | 2007 | 117 | 0.030 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2022 | 913 | 0.030 |
Why?
| | Diet, High-Fat | 1 | 2018 | 253 | 0.030 |
Why?
| | Stem Cells | 1 | 2001 | 603 | 0.030 |
Why?
| | Health Surveys | 2 | 2009 | 513 | 0.030 |
Why?
| | Lipopolysaccharides | 1 | 2000 | 889 | 0.030 |
Why?
| | Survival Analysis | 1 | 2019 | 1320 | 0.030 |
Why?
| | Drug Combinations | 2 | 2011 | 368 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2018 | 855 | 0.030 |
Why?
| | Viruses | 1 | 2018 | 163 | 0.030 |
Why?
| | Telemedicine | 1 | 2025 | 894 | 0.030 |
Why?
| | Fatty Liver | 1 | 2018 | 232 | 0.030 |
Why?
| | Dilatation, Pathologic | 1 | 2015 | 60 | 0.030 |
Why?
| | Gastrointestinal Diseases | 1 | 2017 | 207 | 0.030 |
Why?
| | Neoplasms | 1 | 2011 | 2747 | 0.030 |
Why?
| | Escherichia coli | 1 | 2000 | 838 | 0.030 |
Why?
| | Systole | 1 | 2015 | 175 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 1999 | 1502 | 0.030 |
Why?
| | Drug Users | 1 | 2015 | 42 | 0.030 |
Why?
| | Electric Countershock | 1 | 2015 | 107 | 0.030 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2015 | 1250 | 0.030 |
Why?
| | Absorptiometry, Photon | 1 | 2015 | 266 | 0.030 |
Why?
| | Risk | 1 | 2017 | 907 | 0.030 |
Why?
| | Chi-Square Distribution | 1 | 2015 | 521 | 0.030 |
Why?
| | Phospholipids | 1 | 2015 | 221 | 0.030 |
Why?
| | Death, Sudden, Cardiac | 1 | 2015 | 191 | 0.030 |
Why?
| | Psychometrics | 1 | 2018 | 739 | 0.030 |
Why?
| | Substance Abuse, Intravenous | 1 | 2015 | 122 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2015 | 718 | 0.030 |
Why?
| | Adipose Tissue | 1 | 2018 | 647 | 0.030 |
Why?
| | Interleukin-1beta | 1 | 2015 | 386 | 0.030 |
Why?
| | Phenotype | 1 | 2022 | 3177 | 0.030 |
Why?
| | Analgesics, Opioid | 1 | 2022 | 1123 | 0.020 |
Why?
| | Disease Models, Animal | 2 | 2018 | 4421 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2015 | 910 | 0.020 |
Why?
| | Mice, Inbred C57BL | 2 | 2018 | 5909 | 0.020 |
Why?
| | Follicular Phase | 2 | 2004 | 39 | 0.020 |
Why?
| | Estrogens | 1 | 2015 | 368 | 0.020 |
Why?
| | Fatty Acids | 1 | 2015 | 450 | 0.020 |
Why?
| | Feeding Behavior | 1 | 2018 | 682 | 0.020 |
Why?
| | Defibrillators, Implantable | 1 | 2015 | 306 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2015 | 1498 | 0.020 |
Why?
| | Mothers | 1 | 2018 | 785 | 0.020 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2018 | 663 | 0.020 |
Why?
| | Periodicity | 2 | 2001 | 57 | 0.020 |
Why?
| | Prognosis | 1 | 1999 | 4080 | 0.020 |
Why?
| | Abbreviated Injury Scale | 1 | 2010 | 22 | 0.020 |
Why?
| | Trauma Severity Indices | 1 | 2010 | 111 | 0.020 |
Why?
| | Nasal Polyps | 1 | 2010 | 61 | 0.020 |
Why?
| | Life Expectancy | 1 | 2010 | 71 | 0.020 |
Why?
| | Amides | 1 | 2010 | 100 | 0.020 |
Why?
| | Heart-Assist Devices | 1 | 2015 | 562 | 0.020 |
Why?
| | Reference Values | 1 | 2010 | 807 | 0.020 |
Why?
| | Income | 1 | 2010 | 201 | 0.020 |
Why?
| | Glasgow Coma Scale | 1 | 2010 | 204 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2020 | 6289 | 0.020 |
Why?
| | Heart Transplantation | 1 | 2015 | 715 | 0.020 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2015 | 1115 | 0.020 |
Why?
| | Obstetrics | 1 | 2011 | 177 | 0.020 |
Why?
| | Norgestrel | 1 | 1988 | 2 | 0.020 |
Why?
| | Administration, Intravaginal | 1 | 1988 | 17 | 0.020 |
Why?
| | Medroxyprogesterone | 1 | 1988 | 12 | 0.020 |
Why?
| | Chromatography, Liquid | 1 | 2010 | 453 | 0.020 |
Why?
| | Family Characteristics | 1 | 2010 | 192 | 0.020 |
Why?
| | Gynecology | 1 | 2011 | 179 | 0.020 |
Why?
| | Medroxyprogesterone Acetate | 1 | 1988 | 39 | 0.020 |
Why?
| | Poverty Areas | 1 | 2008 | 41 | 0.020 |
Why?
| | Thyroid Function Tests | 1 | 2008 | 15 | 0.020 |
Why?
| | Single-Blind Method | 1 | 2009 | 289 | 0.020 |
Why?
| | Parity | 1 | 1988 | 110 | 0.020 |
Why?
| | Receptors, Dopamine | 1 | 2008 | 20 | 0.020 |
Why?
| | Sheep | 2 | 2002 | 874 | 0.020 |
Why?
| | Benzodioxoles | 1 | 2010 | 140 | 0.020 |
Why?
| | Intelligence Tests | 1 | 2008 | 63 | 0.020 |
Why?
| | Smallpox | 1 | 2007 | 10 | 0.020 |
Why?
| | Employment | 1 | 2010 | 181 | 0.020 |
Why?
| | Galvanic Skin Response | 1 | 2007 | 25 | 0.020 |
Why?
| | Diphtheria | 1 | 2007 | 22 | 0.020 |
Why?
| | Tetanus | 1 | 2007 | 27 | 0.020 |
Why?
| | Virus Shedding | 1 | 2007 | 48 | 0.020 |
Why?
| | Personal Satisfaction | 1 | 2010 | 215 | 0.020 |
Why?
| | Half-Life | 1 | 2007 | 146 | 0.020 |
Why?
| | Contraindications | 1 | 2007 | 85 | 0.020 |
Why?
| | Commerce | 1 | 2008 | 80 | 0.020 |
Why?
| | Cause of Death | 1 | 2010 | 441 | 0.020 |
Why?
| | Educational Status | 1 | 2010 | 464 | 0.020 |
Why?
| | Lymphocyte Count | 1 | 2007 | 167 | 0.020 |
Why?
| | Plasma Cells | 1 | 2007 | 74 | 0.020 |
Why?
| | Tandem Mass Spectrometry | 1 | 2010 | 568 | 0.020 |
Why?
| | Nerve Fibers, Myelinated | 1 | 2007 | 49 | 0.020 |
Why?
| | Seroepidemiologic Studies | 1 | 2007 | 168 | 0.020 |
Why?
| | Neoplasm Invasiveness | 1 | 2009 | 510 | 0.020 |
Why?
| | Triiodothyronine | 1 | 2007 | 50 | 0.020 |
Why?
| | Apolipoproteins E | 1 | 2007 | 91 | 0.020 |
Why?
| | Photic Stimulation | 1 | 2007 | 256 | 0.020 |
Why?
| | Family Practice | 1 | 2011 | 464 | 0.020 |
Why?
| | Thyroid Hormones | 1 | 2007 | 68 | 0.020 |
Why?
| | Research | 1 | 2010 | 455 | 0.020 |
Why?
| | Thyroid Gland | 1 | 2007 | 92 | 0.020 |
Why?
| | Cerebrovascular Disorders | 1 | 2007 | 97 | 0.020 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2007 | 228 | 0.020 |
Why?
| | Neural Inhibition | 1 | 2007 | 177 | 0.020 |
Why?
| | Age of Onset | 1 | 2008 | 534 | 0.020 |
Why?
| | Safety | 1 | 2008 | 356 | 0.020 |
Why?
| | Motor Skills | 1 | 2007 | 103 | 0.020 |
Why?
| | Patient Satisfaction | 1 | 2010 | 697 | 0.010 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2008 | 561 | 0.010 |
Why?
| | Dopamine Agents | 1 | 2005 | 21 | 0.010 |
Why?
| | Mental Recall | 1 | 2007 | 210 | 0.010 |
Why?
| | Virus Diseases | 1 | 2007 | 215 | 0.010 |
Why?
| | Down-Regulation | 1 | 2007 | 641 | 0.010 |
Why?
| | Gait Disorders, Neurologic | 1 | 2005 | 47 | 0.010 |
Why?
| | Comorbidity | 1 | 2010 | 1664 | 0.010 |
Why?
| | Self Efficacy | 1 | 2008 | 408 | 0.010 |
Why?
| | Dizziness | 1 | 2005 | 94 | 0.010 |
Why?
| | Inpatients | 1 | 2009 | 512 | 0.010 |
Why?
| | Memory, Short-Term | 1 | 2007 | 267 | 0.010 |
Why?
| | Vestibular Diseases | 1 | 2005 | 53 | 0.010 |
Why?
| | Presynaptic Terminals | 1 | 2005 | 94 | 0.010 |
Why?
| | Diet Records | 1 | 2004 | 83 | 0.010 |
Why?
| | Menarche | 1 | 2004 | 53 | 0.010 |
Why?
| | Length of Stay | 1 | 2009 | 1263 | 0.010 |
Why?
| | Chronic Disease | 1 | 2010 | 1820 | 0.010 |
Why?
| | Research Design | 1 | 2010 | 1146 | 0.010 |
Why?
| | Overweight | 1 | 2008 | 588 | 0.010 |
Why?
| | Serotonin | 1 | 2005 | 323 | 0.010 |
Why?
| | Skin | 1 | 2007 | 765 | 0.010 |
Why?
| | Accidental Falls | 1 | 2005 | 216 | 0.010 |
Why?
| | Stress, Psychological | 1 | 2011 | 1133 | 0.010 |
Why?
| | Dopamine | 1 | 2005 | 309 | 0.010 |
Why?
| | Follicular Fluid | 1 | 2002 | 5 | 0.010 |
Why?
| | Adrenal Cortex | 1 | 2002 | 33 | 0.010 |
Why?
| | Heart Failure | 1 | 2015 | 2093 | 0.010 |
Why?
| | Neuraminidase | 1 | 2002 | 25 | 0.010 |
Why?
| | Contraceptives, Oral | 1 | 2002 | 38 | 0.010 |
Why?
| | Hormone Antagonists | 1 | 2002 | 34 | 0.010 |
Why?
| | Osmolar Concentration | 1 | 2002 | 167 | 0.010 |
Why?
| | Dipeptides | 1 | 2002 | 54 | 0.010 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2008 | 1634 | 0.010 |
Why?
| | Thinness | 1 | 2002 | 96 | 0.010 |
Why?
| | Caregivers | 1 | 2010 | 943 | 0.010 |
Why?
| | Dihydro-beta-Erythroidine | 1 | 2001 | 6 | 0.010 |
Why?
| | Postprandial Period | 1 | 2002 | 111 | 0.010 |
Why?
| | Fura-2 | 1 | 2001 | 12 | 0.010 |
Why?
| | Nifedipine | 1 | 2001 | 29 | 0.010 |
Why?
| | Pituitary Gland | 1 | 2002 | 150 | 0.010 |
Why?
| | Nicotinic Antagonists | 1 | 2001 | 36 | 0.010 |
Why?
| | Energy Intake | 1 | 2004 | 513 | 0.010 |
Why?
| | Oxygen Consumption | 1 | 2004 | 715 | 0.010 |
Why?
| | Luteal Phase | 1 | 2000 | 46 | 0.010 |
Why?
| | Area Under Curve | 1 | 2001 | 324 | 0.010 |
Why?
| | Prostaglandin Antagonists | 1 | 2000 | 3 | 0.010 |
Why?
| | Flurbiprofen | 1 | 2000 | 3 | 0.010 |
Why?
| | Depression, Chemical | 1 | 2000 | 20 | 0.010 |
Why?
| | Protein Isoforms | 1 | 2002 | 398 | 0.010 |
Why?
| | HIV Infections | 1 | 2015 | 3022 | 0.010 |
Why?
| | Calcium Channel Blockers | 1 | 2001 | 172 | 0.010 |
Why?
| | Pain Measurement | 1 | 2002 | 554 | 0.010 |
Why?
| | Fluorescent Dyes | 1 | 2001 | 324 | 0.010 |
Why?
| | Genetic Predisposition to Disease | 1 | 2007 | 2375 | 0.010 |
Why?
| | Fever | 1 | 2000 | 308 | 0.010 |
Why?
| | Hypertension | 1 | 2007 | 1254 | 0.010 |
Why?
| | Gene Expression | 1 | 2001 | 1492 | 0.010 |
Why?
| | Calcium | 1 | 2001 | 1192 | 0.010 |
Why?
| | Sleep | 1 | 2002 | 885 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2001 | 4209 | 0.010 |
Why?
| | Rats | 1 | 2001 | 5637 | 0.010 |
Why?
| | Neurons | 1 | 2001 | 1621 | 0.010 |
Why?
| | Mice | 1 | 2007 | 18108 | 0.010 |
Why?
|
|
Carlson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|